Loading
A phase 1/2 trial of E-EDV-D682, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Engeneic Pty Limited, now recruiting.
A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07049055 by Engeneic Pty Limited, with 144 participants planned, started 2026-01-12 and due to reach its primary completion in 2028-09. Interventions recorded: E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.. Conditions listed: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.